{"entity":{"id":"nct07015242","kind":"trial","name":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","aka":["CAROLYN"],"tldr":"A phase 2 trial of Rituximab, Methotrexate, Procarbazine, Temozolomide, Lisocabtagene maraleucel and Fludarabine in non-Hodgkin lymphoma, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, now recruiting.","summary":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma is a phase 2 interventional study registered as NCT07015242 by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, with 65 participants planned, started 2025-11-06 and due to reach its primary completion in 2028-01-09. Interventions recorded: Rituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel and Fludarabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07015242","url":"https://clinicaltrials.gov/study/NCT07015242"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","primary-cns-lymphoma"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["rituximab","methotrexate","procarbazine","temozolomide","lisocabtagene-maraleucel","fludarabine"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07015242","phase":"2","setting":"The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","started":"2025-11-06","startedType":"actual","enrolled":65,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07015242/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"drug":[{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/"},{"id":"methotrexate","kind":"drug","name":"Methotrexate","route":"/drugs/methotrexate/"},{"id":"procarbazine","kind":"drug","name":"Procarbazine","route":"/drugs/procarbazine/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}